Abcellera Biologics is trading 7.56% up now at $7.45 after the August 7, 2026 session, when shares closed at $6.93, as weak payrolls strengthened the broader market and increased expectations for Federal Reserve rate cuts.
- Second-quarter revenue missed estimates.
- Investors may be focusing on the imminent Phase 2 readout for ABCL635 and the company’s pipeline pivot.
- Enrollment is complete, with top-line data expected in Q3.